# A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

> **NCT06937619** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 263 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT06937619
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-21
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-11-10
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06937619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06937619, "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06937619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*